Valganciclovir
98%
- Product Code: 84635
Alias:
Related CAS: 175865-59-5
CAS:
175865-60-8
| Molecular Weight: | 354.36 g./mol | Molecular Formula: | C₁₄H₂₂N₆O₅ |
|---|---|---|---|
| EC Number: | MDL Number: | MFCD05662329 | |
| Melting Point: | Boiling Point: | 629.1°C at 760 mmHg | |
| Density: | Storage Condition: | room temperature, dry |
Product Description:
Valganciclovir is primarily used in the prevention and treatment of cytomegalovirus (CMV) infections, particularly in immunocompromised patients such as those who have undergone organ transplants or are living with HIV/AIDS. It is effective in reducing the risk of CMV disease in kidney, heart, and kidney-pancreas transplant recipients. Additionally, it is used to treat CMV retinitis in AIDS patients, helping to prevent blindness. Valganciclovir is also administered to manage congenital CMV infections in newborns, aiming to reduce the severity of associated complications. Its oral bioavailability makes it a convenient alternative to intravenous therapies, improving patient compliance and quality of life.
Product Specification:
| Test | Specification |
|---|---|
| APPEARANCE | solid |
| PURITY | 97.5-100 |
| Infrared spectrum | Conforms to Structure |
| NMR | Conforms to Structure |
Sizes / Availability / Pricing:
| Size (g) | Availability | Price | Quantity |
|---|---|---|---|
| 0.250 | 10-20 days | ฿5,200.00 |
+
-
|
| 1.000 | 10-20 days | ฿13,300.00 |
+
-
|
| 5.000 | 10-20 days | ฿58,000.00 |
+
-
|
Valganciclovir
Valganciclovir is primarily used in the prevention and treatment of cytomegalovirus (CMV) infections, particularly in immunocompromised patients such as those who have undergone organ transplants or are living with HIV/AIDS. It is effective in reducing the risk of CMV disease in kidney, heart, and kidney-pancreas transplant recipients. Additionally, it is used to treat CMV retinitis in AIDS patients, helping to prevent blindness. Valganciclovir is also administered to manage congenital CMV infections in newborns, aiming to reduce the severity of associated complications. Its oral bioavailability makes it a convenient alternative to intravenous therapies, improving patient compliance and quality of life.
| Mechanism | - |
| Appearance | - |
| Longevity | - |
| Strength | - |
| Storage | - |
| Shelf Life | - |
| Allergen(s) | - |
| Dosage (Range) | - |
| Recommended Dosage | - |
| Dosage (Per Day) | - |
| Recommended Dosage (Per Day) | - |
| Mix Method | - |
| Heat Resistance | - |
| Stable in pH range | - |
| Solubility | - |
| Product Types | - |
| INCI | - |
Cart
No products
Subtotal:
฿0.00
฿0.00
Total :